



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/54, 31/71	A1	(11) International Publication Number: WO 90/01926 (43) International Publication Date: 8 March 1990 (08.03.90)
(21) International Application Number: PCT/US89/03105 (22) International Filing Date: 19 July 1989 (19.07.89) (30) Priority data: 234,034 19 August 1988 (19.08.88) US (71) Applicant: HIMEDICS, INC. [US/US]; 2830 North 28th Terrace, Hollywood, FL 33021 (US). (72) Inventors: GIANNINI, Robert, P. ; 7365 Southwest 9th Court, Plantation, FL 33317 (US). FROMM, Susan, M. ; 6775 Northwest 9th Street, Margate, FL 33063 (US). SU-ARÉZ, José, E. ; 6790 Northwest 186th Street, Apt. 505, Miami, FL 33015 (US). (74) Agents: HIGHET, David, W. et al.; Robbins & Laramie, 2100 Pennsylvania Avenue, N.W., Suite 600, Washington, DC 20037 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: ERYTHROMYCIN MICROENCAPSULATED GRANULES (57) Abstract The invention disclosed is erythromycin microencapsulated granules with activity densities greater than about 0.300 g/ml. These granules are unusually small having diameters less than about 1000 microns. The granules are particularly useful in hand-held flowable material dispensers. A process for manufacturing such granules is also disclosed.		

TITLE OF THE INVENTION

ERYTHROMYCIN MICROENCAPSULATED
GRANULES

BACKGROUND OF THE INVENTION

5 Over the past several years it has become obvious
to health professionals and the pharmaceutical industry
that optimal therapy with existing drugs has not been
achieved with conventional dosage forms (i.e. tablets,
capsules, injectables, suppositories) and dosing
10 regimens. The term "optimal therapy" means the safest,
most rapid, and most convenient amelioration of any
particular disease state. Further, the "safety" of a
dosage form or dosing regimen refers to the frequency
and severity of side reactions. Improvement in therapy
15 can then be defined as any change in the dosage form or
regimen for an existing drug that: 1) reduces the
frequency and severity of side reactions, 2) increases
the rate at which cure or control is achieved, and 3)
decreases the degree of disruption of normal patient
20 activities.

In response to this growing perception, a number of
novel drug delivery systems have been developed and
brought to market. Some good examples are the
transdermal delivery devices such as Nitro-Dur[®] (Key
25 Pharmaceuticals), Nitro-Disc[®] (Searle), Transderm Nitro[®]
(Ciba), Clonidine-TSS[®] (Boehringer-Ingelheim) and
Transderm-Scop[®] (Ciba). Other examples are Theo-Dur[®]
tablets, a sustained release form of theophylline, Theo-
Dur Sprinkle[®] (U.S. Patent 4,587,118) and Slo-Bid[®].
30 Theo-Dur Sprinkle[®] and Slo-Bid[®] are microencapsulated
forms of slow release theophylline that are intended for
use in pediatric patients or other patients who may have
difficulty in swallowing a tablet. The microcapsules
are supplied in hard gelatin capsules. The hard gelatin

-2-

capsules are opened at the point of use by the caregiver and administered in a soft food.

5 This form of drug delivery has significant drawbacks. First, there are a small finite number of capsule sizes marketed, and this limits the physician's ability to prescribe an appropriate dose on the basis of a particular patient's weight, severity of disease, and therapeutic response. Second, there is the possibility of tampering which has become a subject of major concern
10 related to the safety of over-the-counter pharmaceutical products.

Flowable material dispensers such as that described in United States Patent 4,579,256 were developed to overcome these drawbacks. The Flowable Material
15 Dispenser is an adjustable, metering and dispensing package. The dispenser can accurately deliver a granular pharmaceutical product to a patient by pouring the selected dosage onto a small quantity of soft food contained on a spoon prior to swallowing. The dispenser
20 is child- and tamper-resistant, protects the product from the surrounding environment and precisely delivers an adjustable dose well within the compendial requirements for uniformity of dosage units. However, microcapsules that are suitable for use in the Flowable
25 Material Dispenser must meet certain narrow specifications with regard to average particle size, particle size distribution, shape, and active agent concentration.

30 These specifications are generally defined as follows:

-3-

5	Particle size/size distribution (depending on dispenser design)	A: 710 Microns - 1000 Microns B: 590 microns - 840 microns C: 500 microns - 710 microns
	Activity Density (potency x bulk density) g/ml	not less than 0.300
	10 Appearance	nearly spherical
	Flow	freely flowing

Although an acceptable product could be made beyond the limits of these parameters, high potency and small size are required to achieve the necessary bulk density which insures that the largest dose is contained in a volume that is convenient to swallow. Small size is also essential if the particles are to be relatively impalpable when added to soft food. High bulk density allows a dispenser of reasonable size for one hand operation to contain a ten to sixty day supply of drug. Narrow size distribution insures reproducibility of each measured dose and eliminates variation in bulk density due to segregation of sizes. This is critical to a device which measures solid particles by volume. Narrow particle size distribution also implies reproducibility of bulk density from batch to batch. Thus, the same volume will contain the same amount of drug every time in production, which is a new requirement, imposed by the flowable material dispenser but not by prior art delivery systems such as hard gelatin capsules. It is also important that the microcapsules be nearly spherical to impart the flow characteristics that are required at every stage of assembly and use of the dispenser. The nearly spherical aspect of the microcapsules also enhances product elegance.

-4-

Presently available conventional pharmaceutically active granules are generally inappropriate for oral administration with semi-solid food or for use in a hand-held flowable material dispenser. These conventional granules are large and create a noticeable gritty mouthfeel for the patient. Large microgranule size also necessitates an increase in the smallest characteristic dimension of the measuring cylinder and the flow channels of the flowable material dispenser if particle bridging is to be avoided. An increase in the smallest characteristic dimension of the measuring cylinder is also necessary if the requirements of the United States Pharmacopeia for Uniformity of Dosage Units are to be met. As those characteristic dimensions increase, so does the overall size of the flowable material dispenser. Each increase in size of the dispenser results in the loss of a degree of convenience in its use. At some microgranule size larger than 18 mesh (1000 microns), the flowable material dispenser becomes too large to be comfortably hand-held and hand-operated.

Conventional granules are also difficult to accurately dispense from a hand-held flowable material dispenser due to the broad size distribution of granules both within and between batches, as well as the lack of uniform shape of the conventional granules. Erythromycin is uniquely suited for incorporation into a flowable material dispenser because of the complexity of its pharmacodynamic and pharmacokinetic profile. It is well known that dose-related gastrointestinal upsets (epigastric distress, nausea, vomiting and diarrhea) occur commonly with erythromycin administration. It is this adverse effect that the present invention is intended to eliminate. It is believed that much of the gastrointestinal distress that occurs during erythromycin therapy is due to overdose and that

-5-

accurate delivery of the appropriate dose by weight will provide significant therapeutic advantages.

SUMMARY OF THE INVENTION

5 The present invention relates to pharmaceutically active microencapsulated granules comprising erythromycin and a binder which have an unexpectedly high concentration (average activity density greater than about 0.300 g/ml), small size (less than about 1000
10 microns diameter), narrow size distribution, and uniformity of shape (spherical). A number of binders or combinations of binders may be used in the erythromycin granules, including hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, polyvinyl acetate phthalate, polyvinylpyrrolidone, hydroxypropyl
15 methylcellulose, polyethylene glycol, hydroxypropyl cellulose and polyethylene oxide. However, a preferred binder is a mixture of polyethylene oxide and polyethylene glycol.

20 The invention further relates to a preferred method of manufacturing the erythromycin granules using fluidized bed techniques to apply coatings to seeds. The use of fluidized bed techniques also aids in achieving the granule properties of high concentration, small size, narrow size distribution and uniform shape.

25 DETAILED DESCRIPTION OF THE INVENTION

30 The invention relates to pharmaceutically active microencapsulated granules comprising erythromycin and a binder. Such erythromycin granules are particularly useful in flowable material dispensing devices. One such dispensing device is the "Flowable Material Dispenser" disclosed in United States Patent 4,579,256 incorporated herein by reference.

-6-

5 In order for pharmaceutically active granules to be
used in the above-described dispenser, such granules
must exhibit a high concentration of pharmaceutically
active agent, a small size, a narrow size distribution
and a uniformity of shape, preferably spherical. They
must also be resilient enough to withstand packaging on
high speed filling equipment and shipment throughout the
world. The uniformly spherical granules ensure the
accuracy and reproducibility of doses from the
10 dispenser. The properties of high concentration and
small size are necessary for convenience of
administration by minimizing the amount of granules the
patient has to swallow. The high concentration and
small size, along with the narrow size distribution of
15 uniformly spherical granules are also desirable so that
the granules do not create an unpleasant gritty feeling
in the patient's mouth when the granules are ingested
with the food on which they are dispensed. Small
average size is also necessary if the flowable material
20 dispenser is to be kept small enough to be hand-held and
hand-operated.

The erythromycin granules which meet the above
concentration, size and shape requirements comprise a
starting seed which has an active coating applied
25 thereto. The active coating comprises erythromycin and
a binder.

Erythromycin is a well-known antibiotic which is
available as white or slightly yellow crystals or
powder. It is slightly hygroscopic and has a pK_a of 8.7.
30 Erythromycin is very slightly soluble in water, and
freely soluble in alcohol, chloroform, ether and
acetone, and moderately soluble in amyl acetate and
ethylene dichloride.

Suitable binders for use with the erythromycin
include hydroxypropyl methylcellulose phthalate,
35 polyvinyl- pyrrolidone, hydroxypropyl methylcellulose,

-6-

In order for pharmaceutically active granules to be used in the above-described dispenser, such granules must exhibit a high concentration of pharmaceutically active agent, a small size, a narrow size distribution and a uniformity of shape, preferably spherical. They must also be resilient enough to withstand packaging on high speed filling equipment and shipment throughout the world. The uniformly spherical granules ensure the accuracy and reproducibility of doses from the dispenser. The properties of high concentration and small size are necessary for convenience of administration by minimizing the amount of granules the patient has to swallow. The high concentration and small size, along with the narrow size distribution of uniformly spherical granules are also desirable so that the granules do not create an unpleasant gritty feeling in the patient's mouth when the granules are ingested with the food on which they are dispensed. Small average size is also necessary if the flowable material dispenser is to be kept small enough to be hand-held and hand-operated.

The erythromycin granules which meet the above concentration, size and shape requirements comprise a starting seed which has an active coating applied thereto. The active coating comprises erythromycin and a binder.


Erythromycin is a well-known antibiotic which is available as white or slightly yellow crystals or powder. It is slightly hygroscopic and has a pK_a of 8.7. Erythromycin is very slightly soluble in water, and freely soluble in alcohol, chloroform, ether and acetone, and moderately soluble in amyl acetate and ethylene dichloride.

Suitable binders for use with the erythromycin include hydroxypropyl methylcellulose phthalate, polyvinyl- pyrrolidone, hydroxypropyl methylcellulose,

-7-

polyethylene glycol, hydroxylpropyl cellulose, polyethylene oxide, cellulose acetate phthalate, polyvinyl acetate phthalate and mixtures thereof. A preferred binder comprises a mixture of polyethylene oxide and polyethylene glycol. The use of the polyethylene oxide/polyethylene glycol binder aids in achieving the required granule properties of the high concentration, small size, narrow size distribution, uniform shape, resiliency, and rapid dissolution in basic media.

Polyethylene oxide is a polymer resin having the formula:



where n determines the degree of polymerization and may range from about 2,000 to about 100,000 depending upon the viscosity grade of the resin. Each repeating unit shown above has a molecular weight of 44, and therefore the corresponding molecular weights of the resins range from about 100,000 to about 5 million.

Preferred polyethylene oxide resins for use in microencapsulated granules have molecular weights ranging from about 100,000 to about 900,000, and viscosities of about 10 cps of 5% solution to about 16,000 cps of 5% solution at 25°C as measured by Brookfield® viscometer or suitable equivalent instrumentation. Preferred polyethylene oxide resins are supplied as a white powder with a melting point of 65°C (149°F). Chemically, polyethylene oxide resins are polyethers, are nonionic, and are water soluble. Polyethylene oxide resins are supplied by Union Carbide under the trademark Polyox®.

The other component of the binder, polyethylene glycol, is also a polymer resin and has the formula:



-8-

where n is greater than or equal to 4, and generally ranges between 4 and about 210. Polyethylene glycol may be prepared by reacting ethylene glycol with ethylene oxide in the presence of sodium hydroxide (NaOH) at temperatures in the range of 120°C (248°F) to 135°C (275°F) under a pressure of about 4 atmospheres. Depending on its molecular weight, polyethylene glycol may be a clear viscous liquid or a white waxy solid at room temperature.

Polyethylene glycol with molecular weights between about 190 and about 900 are viscous liquids, while those with molecular weights of about 1000 to about 9000 are waxy solids. The viscosity of polyethylene glycol is measured at 99°C (210°F) and ranges from about 4.3 centistokes to about 900 centistokes. The freezing point of polyethylene glycol ranges from about 4°C (39°F) to about 63°C (145°F). As the molecular weight of polyethylene glycol increases its water solubility, vapor pressure, hygroscopicity, and solubility in organic solvents decreases. In contrast, the freezing or melting range, specific gravity, flash point and viscosity increases as its molecular weight increases. Preferred polyethylene glycols are those with molecular weights from about 1000 to about 9000.

In the preferred binder, polyethylene oxide is present as about 52% by weight to about 72% by weight of the binder and polyethylene glycol is present as about 28% by weight to about 48 % by weight of the binder. In a particularly preferred binder, polyethylene oxide of molecular weight 100,000 is present as about 62% by weight of the binder and polyethylene glycol 8000 is present as about 38% by weight of the binder.

In the active coating, the weight ratio of erythromycin to polyethylene oxide/polyethylene glycol binder is preferably between about 5 to 1 and about 15 to 1. It is believed that there is an interaction of weak long

-9-

range forces such as complexation, hydrogen bonding or Van der Wahl's forces between the erythromycin and the polyethylene oxide/polyethylene glycol binder of the active coating. Such an interaction is theorized based on a very slow dissolution rate for active seeds comprising 92% by weight erythromycin and 8% by weight polyethylene oxide, in simulated intestinal fluid ("SIF"). Both erythromycin alone and polyethylene oxide alone are very soluble in SIF.

Additional evidence of a reaction between erythromycin and the polyethylene oxide/polyethylene glycol binder is found in the fact that the dissolution of an active seed comprising 95% by weight erythromycin and 5% by weight polyethylene oxide increases while the resilience of the seed decreases. Further, when a combination of polyethylene oxide and polyethylene glycol is used as the binder at the 8% level by weight, the dissolution remains rapid but the seeds are not as resilient as with 8% polyethylene oxide alone. This data also implies that the interaction between erythromycin and polyethylene glycol is not as strong as that between erythromycin and polyethylene oxide. Finally, when additional amounts of polyethylene oxide and polyethylene glycol are used as a protective coating, (i.e., intimate contact between molecules of erythromycin and molecules of these substances is avoided) the dissolution is also rapid and resilience increases. The data pertaining to this postulated interaction is presented in Example 14. It can also be seen in Example 10 that the presence of ethyl acetate increased the resilience of seeds manufactured with hydroxypropylmethcellulose phthalate as the binder. However, that resilience was lost when the ethyl acetate was removed from the process. This indicates that a similar interaction occurs between erythromycin and ethyl acetate.

-10-

When applied to the starting seed, the active coating is applied as an active coating composition comprising erythromycin, a binder and a solvent. The coating composition is in the form of a solution or a suspension. Examples of suitable solvents for use in the coating composition include water, ethanol, methanol, isopropanol, acetone, methylene chloride, chloroform, ethyl acetate, carbon tetrachloride, benzene, methyl ethyl ketone and combinations thereof. Any number of these solvents may be combined to achieve the proper balance between solubility of binder and erythromycin, while still maintaining a pumpable and sprayable viscosity. Such a desired viscosity is between about 5 cps and about 100 cps as measured by Brookfield[®] viscometer or suitable equivalent instrumentation. Although the polyethylene oxide/polyethylene glycol binder is preferably dissolved in the solvent, the pharmaceutically active agent may be either dissolved or suspended in the solvent.

The preferred solvent is a mixture of about 70-90% by weight methanol and about 10-30 % by weight purified water. A particularly preferred solvent is a mixture of 80% by weight methanol and 20% by weight purified water. The preferred solution or suspension of erythromycin, binder and solvent, contains about 15-40% by weight erythromycin, about 1%-4% by weight polyethylene oxide/polyethylene glycol binder, and the remainder solvent. A particularly preferred solution or suspension contains about 23% by weight to 25% by weight erythromycin and about 2% by weight binder. As high an amount of solids as is possible in the solution or suspension is preferred in order to reduce the process time for manufacture of the granules.

When preparing the active coating composition, the solvent mixture of methanol and water is first mixed. The binder is then added to the solvent mixture and then

-11-

the erythromycin is blended in to complete the composition.

Commonly used inert starting seeds on which the active coating composition is applied include nonpareil seeds, sucrose crystals, silica gel and ion exchange resins. The preferred size range for inert starting seeds is inversely related to the average daily dose of the drug in question. In the case of high dose drugs like erythromycin, it is desirable to start with the smallest seed possible to obtain the greatest finished drug content. This minimizes the total volume of microcapsules that must be ingested. However, the difficulty encountered in coating discrete seeds smaller than 175 microns increases dramatically. A 60/80 mesh (177 microns-250 microns) starting seed represents the smallest size that can be dealt with without using extraordinary measures. If drug crystals or granulation are to be used as the starting material rather than an inert seed, the preferred starting size would be between 25 and 40 mesh (approx. 420-700 microns). The larger seed size serves to reduce the time required to apply additional drug to the seeds to meet the finished product seed size requirements of diameters less than 1000 microns. Usually, drug crystals or granulation of large size and suitable physical strength are not available on the open market for use as starting materials. Therefore, inert starting seeds are most commonly used in the present invention.

The size of the finished granule is less than about 18 mesh (less than about 1000 microns diameter) and a preferred size is between about 18 mesh and about 25 mesh (about 710 microns to about 1000 microns diameter). The preferred starting seeds for the erythromycin microgranules are (60/80) sucrose crystals. The 25/30 nonpareil seeds are usually used with drugs which require lower daily doses, and the 60/80 sucrose

-12-

crystals are usually used with drugs which require a higher daily dose.

5 In one embodiment, the active coating composition is applied to the starting seed by use of a rotor granulator. Examples of conventional rotor granulators are the Vector Freund Spir-A-Flow[®] (one embodiment described in United States Patent 3,711,319) and the Glatt rotor granulator. In general, a rotor granulator comprises a processing chamber with a rotor at its lower
10 portion. Air is introduced at the level of the rotor for fluidization of the product bed. This air may enter the chamber through the opening between the rotor and the stator and/or through a second opening about midway across the radius of the rotor. This introduction of
15 air results in a spiral and twisting air pattern within the chamber. When the inert starting seeds are introduced into the chamber, the combination of rotor and air circulation pattern is purported to provide higher individual particle densities, and rounder and
20 smoother seeds than conventional fluid-bed systems such as Wurster columns and conventional Glatt fluidized beds.

Once the starting seeds have been fluidized in the rotor granulator, the solution or suspension of binder
25 and erythromycin is introduced through spray guns mounted in the periphery of the stator near the bottom of the product chamber or near the top of the product chamber to spray on the product from above. Although the starting seeds could also be coated using
30 conventional fluidized beds, the rotor granulator is purported to produce a more evenly coated product with a higher concentration of active agent and a greater uniformity of spherical shape of each coated seed.

35 In addition to the purported benefit derived from use of the rotor granulator, the polyethylene oxide/polyethylene glycol binder also contributes to the

-13-

unexpectedly high concentration of erythromycin in each coated seed. The high concentration of erythromycin in the coated seeds is not achievable with conventional binders even when such coated seeds are manufactured with a rotor granulator.

Despite the purported benefits of the rotor granulator, it has been found that conventional fluidized bed techniques produce erythromycin microencapsulated granules which meet all of the requirements for use in a hand-held flowable material dispenser. Such fluidized bed techniques are well known to those skilled in the pharmaceutical manufacturing art. With regard to the present invention, fluidized bed techniques are the preferred method of manufacture for erythromycin microencapsulated granules.

After the pharmaceutically active seed has been produced, a protective coating is preferably applied to it. The protective coating is preferably applied to the active seed by using a rotor granulator, although other conventional fluidized beds may be used instead of the rotor granulator. Following application of the protective coating, alternate applications of the active coating and the protective coating may optionally be applied to the coated seed until the desired concentration of erythromycin is present in the microencapsulated granule.

A suitable protective coating comprises a mixture of about 52% by weight to about 72% by weight polyethylene oxide and about 28% by weight to about 48% by weight polyethylene glycol. A preferred protective coating comprises a mixture of about 62% by weight polyethylene oxide and about 38% by weight polyethylene glycol.

The preferred polyethylene oxide is one with a molecular weight of about 100,000 to about 900,000 and the preferred polyethylene glycol has a molecular weight

-14-

between about 1000 and about 9000. The mixture is produced in the same manner and under the same conditions as the binder described above, and is dissolved in a suitable solvent such as those described above to produce a protective coating composition.

A preferred protective coating composition contains about 10% by weight of the polyethylene oxide/polyethylene glycol mixture and about 90% water as the solvent. Water is the preferred solvent because erythromycin is not highly soluble in water and therefore there is little tendency for the active coating to dissolve or interact with the protective coating composition. The interaction of the erythromycin and the components of the protective coating when brought into intimate contact (as in the active coating composition), was seen to unacceptably slow the dissolution of the finished product in basic media. This protective coating composition also resulted in the strongest granules (i.e. was able to withstand extended processing times).

Another advantage of the protective coating is that it permits the use of acetone as a solvent in an enteric coating composition which is applied to the active seed after a desired concentration of erythromycin has been achieved. Acetone and erythromycin have an undesired reaction which inhibits the removal of acetone from the finished product. The protective coating prevents this reaction. The prevention of this reaction is important because acetone is a preferred solvent for the enteric coating composition, and high levels of residual acetone in the finished product are deemed unacceptable toxicologically and with regard to stability.

The desired concentration of pharmaceutically active agent in each microencapsulated granule is dependent on the nature of a course of therapy (dosage level and duration) for a particular drug, the storage

-15-

capacity of the device that will be used to dispense the granules and the number of microcapsules that can be conveniently delivered to a spoonful of semisolid food and swallowed. In the case of erythromycin, it is
5 desired that the microencapsulated granules have as high a concentration as possible.

In a preferred embodiment, the erythromycin micro-encapsulated granules are dispensed from a device such as that described in United States Patent 4,579,256.
10 Microencapsulated granules of erythromycin used in these dispensers should have an activity density greater than about 0.300 g/ml and preferably about 0.420 g/ml to about 0.470 g/ml. Activity density is defined as the mass activity of active agent per unit of volume and is
15 equal to the bulk density of the finished product (pharmaceutically active microencapsulated granule) in g/ml multiplied by the potency of the finished product in g/g. In order to achieve the preferred activity density, it is necessary to produce a microencapsulated
20 granule of as high a potency and bulk density as possible.

Since erythromycin has better absorption characteristics in the small intestine than in the stomach, an enteric coating is preferably applied to the
25 erythromycin microencapsulated granules. Such differing absorptive characteristics are thought to be dependent on the comparative acidity of the stomach and the small intestine. The stomach is more acidic (pH of about 1.0) than the small intestine (pH of about 7.0). Erythromycin
30 is not stable in an acidic environment.

An enteric coating may also be applied to granules containing pharmaceutically active agents which are more irritating to the mucosa of the stomach than to the intestinal mucosa. Examples of pharmaceutically active
35 agents with this characteristic are well known to those of ordinary skill in the art and include aspirin and

-16-

divalproex sodium. Suitable enteric coatings may comprise cellulose acetate phthalate, polyvinyl acetate phthalate, acrylic resins such as Eudragit L[®], shellac, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate or combinations thereof.

A particularly useful enteric coating for application to the microencapsulated granules comprises between 3% (w/w) and 10% (w/w) hydroxypropyl methylcellulose phthalate. The enteric coating is applied as a enteric coating composition comprising a dispersion of hydroxypropyl methylcellulose phthalate in a solvent comprising either acetone alone or a combination of acetone and methanol. When a solvent combination of acetone and methanol is used, the preferred combinations comprise either about 75% (w/w) acetone and about 25% (w/w) methanol or about 50% (w/w) acetone and about 50% (w/w) methanol. Based on superior dissolution rates and taste-masking properties, a most preferred enteric coating comprises about 6% (w/w) hydroxypropyl methylcellulose phthalate applied in an enteric coating composition comprising a solvent mixture of about 75% (w/w) acetone and about 25% (w/w) methanol. It has been found that this particular ratio of the two solvents produces a finished product of greater stability.

Another suitable enteric coating composition comprises about 5% (w/w) to about 10% (w/w) hydroxypropyl methylcellulose phthalate and a solvent comprising about 75% (w/w) methylene chloride and about 25% (w/w) methanol. The enteric coating applied by this composition is preferably present as about 3% (w/w) to about 10% (w/w) of the microencapsulated granule.

As with the other coating compositions, the enteric coating composition is preferably applied using a fluidized bed technique. Following the enteric coating application, the microencapsulated granules may be subjected to a drying step. The microencapsulated

-17-

granules are dried in the rotor granulator or fluidized bed processor at a temperature between about 55°C (131°F) and about 80°C (176°F).

Although the drying step reduces the residual solvent levels to a safe and acceptable level, lower residual solvent levels can be reached by performing an optional second drying step. The optional drying step is performed under a vacuum of 30 mm Hg at about 70°C (158°F) for about 23 hours and results in undetectable residual solvent levels in the microencapsulated granules.

An additional optional step after the microencapsulated granules have been dried is the addition of an antistatic agent. About 0.75% by weight (based on the final product weight) of a suitable antistatic agent is added in the fluidized bed or rotor granulator after the final drying step. The fluidized bed is run for about five minutes to distribute the antistatic agent onto the microencapsulated granules. This amount of antistatic agent is sufficient to coat the granules and prevent the granules from sticking to the sides of the flowable material dispenser. The prevention of adherence between the granules and the dispenser serves to reduce variability in dosing which is more common when an antistatic agent is not used.

Suitable antistatic agents include silicon dioxide, polacrillin, talc, magnesium stearate, calcium stearate, stearic acid and combinations thereof. The preferred antistatic agent is silicon dioxide. Silicon dioxide, unlike many of the other suitable antistatic agents, serves the dual purpose of being a moisture scavenger. The elimination of the excess moisture which usually develops from condensation due to climatic changes during shipping and storing, also aids in eliminating variable dosing problems and flow problems with the granules.

-18-

The finished erythromycin microgranules may be used in a variety of dosage delivery system, including tablets, capsules and flowable material dispensers. When used in a tablet delivery system, the erythromycin microgranules are compressed or formed into a tablet using conventional pharmaceutical tableting techniques. When used in a capsule delivery system, the erythromycin microgranules are used to fill water soluble capsules using conventional pharmaceutical capsule manufacturing techniques. When used in a flowable material dispenser delivery system, the erythromycin microgranules are used to fill the flowable material dispenser.

The features and advantages of the invention are further demonstrated by the following examples. In this specification and in the following examples, all parts and percentages are by weight and all temperatures are in degrees centigrade unless expressly stated to be otherwise.

Example 1

Preparation of Microencapsulated Erythromycin Granules

A solution of 50.0 grams polyethylene oxide NF and 30.0 grams polyethylene glycol 8000 NF in a mixture of 2400 grams Methyl Alcohol NF and 600 grams Purified Water USP was prepared. The polyethylene oxide/polyethylene glycol 8000 solution was then mixed with 925 grams of Erythromycin Dihydrate USP for seven minutes until a translucent solution ("active coating composition") was formed. Another solution was made from 19.1 grams Polyethylene Oxide NF and 11.5 grams Polyethylene Glycol 8000 NF in 275.4 grams Purified Water USP ("protective coating composition").

The active coating composition was applied (sprayed) onto 500 grams of Sucrose NF (starting seeds) to form

-19-

active seeds. The starting seeds were 60/80 mesh size. The application of the coating took place after the sucrose had been fluidized in a Vector Freund Spir-A-Flow[®] rotor granulator. Once all the active coating composition had been sprayed onto the sucrose, the pump tubing was disconnected and rinsed with Methyl Alcohol NF.

After the pump tubing was reconnected, the protective coating composition of polyethylene oxide and polyethylene glycol 8000 in water was applied (sprayed) onto the active seeds which had been fluidized in the rotor granulator. Once all of the protective coating composition had been applied to the seeds, the product was dried in the rotor granulator at 55°C (131°F) for 15 minutes. The product was discharged into a suitable container and labelled Erythromycin Active I Seeds.

A portion (500 grams) of the Active I Seeds were returned to the Spir-A-Flow[®]. A second active coating composition was prepared as described above and applied (sprayed) onto the Active I Seeds. After the tubing was rinsed with methanol as described above, a protective coating composition prepared as described above was then applied (sprayed) onto the seeds. The product was dried as described above, discharged into a suitable container and labelled Active II Seeds.

A portion (614 grams) of the Active II seeds were returned to the Spir-a-flow[®]. A third active coating composition was prepared using 49.3 grams of Polyethylene Oxide NF, and 29.6 grams of Polyethylene Glycol 8000 NF in a mixture of 236.7 grams of Methyl Alcohol NF and 592 grams of Purified Water USP. The polyethylene oxide/polyethylene glycol 8000 solution was then mixed with 907.5 grams of Erythromycin Dihydrate, USP, for 7 minutes until an active coating composition was formed. The active coating composition was applied to the Active II seeds, after which the tubing was

-20-

rinsed (sprayed) with methanol. A third protective coating composition which had been prepared with 19.1 grams of Polyethylene Oxide NF and 11.5 grams of Polyethylene Glycol 8000 NF and 275.4 grams of Purified Water USP was applied to the seeds. The seeds were dried at about 55°C (131°F) for 15 minutes. The seeds were discharged from the column and labelled Active III seeds. The tubing for the rotor granulator was again rinsed with methanol.

An enteric coating composition was then prepared by mixing 76.6 grams Hydroxypropyl Methylcellulose Phthalate 20073 NF into a mixture of 1091 grams Acetone NF and 364 grams Methyl Alcohol NF. A portion (1200 grams) of the Active III Seed were then fluidized in the rotor granulator, and the enteric coating composition applied by spraying the seeds. When all of the enteric coating composition had been applied, the seeds were dried in the rotor granulator at about 70°C (158°F) until a constant product temperature was obtained (58°C, 136°F) after about 45 minutes.

Finally, 9.6 grams of silicon dioxide NF was added to the dried fluidized granules in the rotor granulator. The rotor granulator was run for about five minutes, after which time the granules were uniformly coated with the silicon dioxide.

The resulting erythromycin dihydrate microencapsulated granules had an activity density of 0.456 g/ml and were of uniform small size and uniform spherical shape. About 90% of the final granules were between 700 microns and 1000 microns in diameter.

Table 1 below, shows the amounts of each ingredient in the final product.

-21-

Table 1

	Qty. per 250 mg dose of Erythromycin base (mg)	Ingredient	Qty. per Kg Batch size (g)
5	271 *	Erythromycin Dihydrate USP	799
10	20.3	Hydroxypropyl Methyl- cellulose Phthalate 200731 NF	59.6
	20.7	Polyethylene Oxide NF (MW 10,000)	60.8
15	12.4	Polyethylene Glycol 8000 NF	36.5
	12.4	Sucrose NF	36.6
	2.6	Silicon Dioxide NF	7.5
	805 **	Methanol NF	2370
	288 **	Acetone NF	849
20	262 **	Purified Water USP	771

* Based on theoretical activity of 92%. The actual weight of erythromycin dihydrate used is calculated on a lot to lot basis according to the following formula:

25

Actual amount of erythromycin dihydrate to charge =

$$\frac{\text{Theoretical Amount to Charge* (92\%)}}{\text{Measured Activity (\%)}}$$

30

** Removed during processing

-22-

Example 2

Reproducibility Study

Using the process described in Example 1, above, three batches of final product were manufactured. A 24-fold buildup of the starting seeds was used to produce the final product for each batch.

The final theoretical potency for each batch was approximately 730 mg/g. The final product of each batch was tested for potency and bulk density, and the results are set forth below in Table 2.

Table 2

	Bulk Density	Theore- tical Potency	Actual Potency	Theore- tical Activ- ity Densi- ty	Actual Activ- ity Densi- ty
<u>Batch</u>	<u>(G/ML)</u>	<u>(G/G)</u>	<u>(G/G)</u>	<u>(G/ML)</u>	<u>(G/ML)</u>
871103C	.638	.728	.737	.464	.470
871116A	.625	.730	.738	.456	.461
871117B	.640	.732	.726	.468	.468

The bulk densities, actual potencies and actual activity densities show a consistently reproducible final product. The average actual activity density for the three batches was 0.465 g/ml which was acceptable. This average value represents the average bulk density of the three batches multiplied by the average actual potency of the three batches.

-23-

Example 3

Effect of Acetone/Methanol Ratio in
the Enteric Coating Composition on
the Dissolution Profile and Taste
Mask Characteristics of the Final
Product

Three batches of erythromycin microencapsulated granules were manufactured following the procedure set forth in Example 1 above. However, the enteric coating composition of each batch was varied by the amount of acetone present in the solvent. Batch 871105A had an enteric coating composition solvent of 100% by weight acetone, Batch 871103C had an enteric coating composition solvent mixture of 75% by weight acetone and 25% by weight methanol, and Batch 871109A had an enteric coating composition solvent of 50% by weight acetone and 50% by weight methanol.

The dissolution of the final product of each batch was tested as well as the taste. The results of the test are set forth below in Table 3.

-24-

Table 3

	Batch	%Ct. Wt.	Time (min)	% Dissolved	Comments
5	871105A	6	90 120	* 70.7 * 85.5	Bitter taste Acetone (100%)
	871103C	6	90 120	79.3 95.6	No taste Ace/Meth (75/25)
10	871109A	6	90 120	* 76.3 * 87.8	Slightly bitter Ace/Meth (50/50)

Dissolution testing for enteric coated pellets was performed as follows:

- 15 90 minutes = 60 minutes in simulated gastric fluid ("SGF") and 30 minutes in simulated intestinal fluid ("SIF").
- 120 minutes = 60 minutes in SGF and 60 minutes in SIF.
- 20 * Dissolution data based on theoretical potency. All other results based on measured potency.

- 25 The erythromycin microencapsulated granules with an enteric coating composition solvent comprising a mixture of 75% by weight acetone and 25% by weight methanol (Batch 871103C) not only had the best dissolution characteristics, but also had the best taste mask characteristics.

Example 4

30 Stability of Erythromycin
Microencapsulated Granules

Three batches of erythromycin microencapsulated granules were prepared in accordance with Example 1 (Batches 871103C-1, 871116A-1 and 871109A-1). Batches

-25-

871103C-1 and 871116A-1 were prepared with an enteric coating composition solvent comprising 75% by weight acetone and 25% by weight methyl alcohol. However, Batch 871109A-1 was prepared with a mixture comprising 50% by weight acetone and 50% by weight methyl alcohol as the enteric coating composition solvent.

After manufacture, finished microgranules of each batch were sealed in prototype hiMedics, Inc.'s Flowable Material Dispensers (U.S. 4,579,256). Stability data was determined following storage at room temperature and at elevated temperature and humidity. The stability data for each batch (871103C-1, 871116A-1 and 871109A-1) is presented below in Tables 4A, 4B and 4C, respectively.

Table 4A

Batch: #871103C-1 Batch Size (KG): 1.3 Theoretical Potency (mg/g): 723.0

Parameter	Initial	3M RT	6M RT	Specifications
Potency (mg/g)	726.0	823.0	769.0	658.0-840.0 act/gr
Potency (% Theory)	99.7	113.0	105.6	
Potency (% of Initial)	100.0	113.4	105.9	90.0-115.0 % LC
Loss of Dryness (%loss)	0.35	0.64	0.93	Report Value
Water (%)	3.52	2.10	2.96	Report Value
Appearance	Pass	Pass	Pass	Free Flowing White to Off-white
Odor	None	None	None	Uniform Spheres Report Odor
Taste	Pass	Pass	Pass	None to Slight Bitter
Bulk Density (g/ml)	0.638	0.645	0.615	Report Value
Dissolution Fluid: Acid & SIF @ 50 rpm Interval 120 mins (% Release)	92.1	92.8	92.6	NLT 80% @ 120 min
Storage Conditions:	RT = Room Temperature 15-30°C 37/75 = 35 - 40°C with 70 - 80 % Relative Humidity M = Month			

-27-

Table 4A - cont'd

Batch: #871103C-1	Batch Size (KG): 1.3	Theoretical Potency (mg/g): 723.0			
Parameter	Initial 1M 37/75	2M 37/75	3M 37/75	6M 37/75	Specifications
Potency (mg/g)	726.0	739.0	784.0	796.0	759.0 658.0-840.0 act/gr
Potency (% Theory)	99.7	105.5	107.7	109.3	104.3
Potency (% of Initial)	100.0	101.8	108.0	109.6	104.5
Loss of Dryness (%loss)	0.35	1.96	2.24	1.80	2.73
Water (%)	3.52	3.87	6.14	3.75	4.52
Appearance	Pass	Pass	Pass	Pass	Free Flowing White to Off-white Uniform Spheres Report Odor
Odor	None	None	None	None	None
Taste	Pass	Pass	Pass	Pass	None to Slight Bitter
Bulk Density (g/ml)	0.638	0.641	0.661	0.653	0.627
Dissolution Fluid: Acid & SIF @ 50 rpm Interval 120 mins (% Release)	92.1	91.1	95.7	86.2	77.6
Storage Conditions:	RT = Room Temperature 15-30°C				
	37/75 = 35 - 40°C with 70 - 80 % Relative Humidity				
	M = Month				

SUBSTITUTE SHEET

Table 4B

Batch: #871116A-1 Batch Size (KG): 1.0 Theoretical Potency (mg/g): 730.00

Parameter	Initial	3M RT	6M RT	Specifications
Potency (mg/g)	761.0	733.0	752.0	658.0-840.0 act/gr
Potency (% Theory)	104.2	105.8	103.0	
Potency (% of Initial)	100.0	105.4	98.8	90.0-115.0 % LC
Loss of Dryness (% loss)	0.05	0.35	0.50	Report Value
Water (%)	2.91	2.62	3.36	Report Value
Appearance	Pass	Pass	Pass	Free Flowing White to Off-white
Odor	None	None	None	Uniform Spheres
Taste	Pass	Pass	Pass	Report Odor
Bulk Density (g/ml)	0.625	0.632	0.601	None to Slight Bitter
Dissolution Fluid: Acid & SIF @ 50 rpm Interval 120 mins (% Release)	93.0	83.8	92.5	Report Value
Storage Conditions:	RT = Room Temperature 15-30°C			NLT 80% @ 120 min
	37/75 = 35 - 40°C with 70 - 80 % Relative Humidity			
	M = Month			

- 29 -

Table 4B - cont'd

Batch: #871116A-1	Batch Size (KG): 1.0	Theoretical Potency (mg/g): 730.00							
Parameter	Initial 1M	37/75	2M	37/75	3M	37/75	6M	37/75	Specifications
Potency (mg/g)	761.0	734.0	766.0	798.0	764.0	658.0-840.0	act/gr		
Potency (% Theory)	104.2	105.5	104.9	109.3	104.7	90.0-115.0	% LC		
Potency (% of Initial)	100.0	96.5	100.7	104.6	100.4				
Loss of Dryness (% loss)	0.05	2.17	1.89	1.55	2.47	Report Value			
Water (%)	2.91	4.40	5.55	4.21	4.75	Report Value			
Appearance	Pass	Pass	Pass	Pass	Pass	Free Flowing White to Off-white			
Odor	None	None	None	None	None	Uniform Spheres			
Taste	Pass	Pass	Pass	Pass	Pass	Report Odor			
Bulk Density (g/ml)	0.625	0.625	0.655	0.631	0.606	Report Value			
Dissolution Fluid:									
Acid & SIF @ 50 rpm									
Interval 120 mins									
(% Release)									
Storage Conditions:	RT = Room Temperature 15-30°C	93.0	90.2	93.5	88.4	74.8	NLT 80% @ 120 min		
	37/75 = 35 - 40°C with 70 - 80 % Relative Humidity								
	M = Month								

SUBSTITUTE SHEET

Table 4C

Batch: #871109A-1 Batch Size (KG): 1.2 Theoretical Potency (mg/g): 731.00

Parameter	Initial	3M RT	6M RT	Specifications
Potency (mg/g)	735.0	786.0	772.0	658.0-840.0 act/gr
Potency (% Theory)	100.5	107.5	105.6	
Potency (% of Initial)	100.0	106.9	105.0	90.0-115.0 % LC
Loss of Dryness (%loss)	0.37	0.64	0.73	Report Value
Water (%)	2.98	3.02	3.56	Report Value
Appearance	Pass	Pass	Pass	Free Flowing White to Off-white
Odor	None	None	None	Uniform Spheres
Taste	Pass	Pass	Pass	Report Odor
Bulk Density (g/ml)	0.651	0.621	0.590	None to Slight Bitter
Dissolution Fluid: Acid & SIF @ 50 rpm				Report Value
Interval 120 mins				
(% Release)				
Storage Conditions:				
RT	90.4	83.6	83.7	NLT 80% @ 120 min
37/75	= Room Temperature 15-30°C			
M	= 35 - 40°C with 70 - 80 % Relative Humidity			
	= Month			

-31-

Table 4C - cont'd

Batch: #871109A-1	Batch Size (KG): 1.2	Theoretical Potency (mg/g): 731.00							
Parameter	Initial 1M	37/75	2M	37/75	3M	37/75	6M	37/75	Specifications
Potency (mg/g)	735.0	735.0	754.0	780.0	804.0	658.0-840.0	act/gr		
Potency (% Theory)	100.5	100.5	103.9	106.7	110.0				
Potency (% of Initial)	100.0	100.0	102.6	106.1	109.4	90.0-115.0 % LC			
Loss of Dryness (%loss)	0.37	1.55	2.05	2.16	2.61	Report Value			
Water (%)	2.98	3.97	4.77	4.46	3.84	Report Value			
Appearance	Pass	Pass	Pass	Pass	Pass	Free Flowing White to Off-white			
Odor	None	None	None	None	None	Uniform Spheres Report Odor			
Taste	Pass	Pass	Pass	Pass	Pass	None to slight Bitter			
Bulk Density (g/ml)	0.651	0.644	0.670	0.636	0.617	Report Value			
Dissolution Fluid:									
Acid & SIF @ 50 rpm									
Interval 120 mins									
(% Release)									
Storage Conditions:	90.4	81.3	82.5	82.2	76.2	NLT 80% @ 120 min			
	RT = Room Temperature 15-30°C								
	37/75 = 35 - 40°C with 70 - 80 % Relative Humidity								
	M = Month								

SUBSTITUTE SHEET

-32-

5 The stability data for all three batches was satisfactory, although it is clearly shown that the microgranules manufactured with a 75/25 weight % mixture of acetone and methyl alcohol as the solvent for the enteric coating composition (Batches 871103C-1 and 871116A-1) had better dissolution characteristics than the same microgranules manufactured with a 50/50 weight % mixture of acetone and methyl alcohol as the enteric coating composition solvent (Batch 871109A-1).

10

Example 5

Effect of Percent Enteric Coat Weight
on Dissolution and Taste Mask

15 Four batches of erythromycin microencapsulated granules were manufactured in accordance with the procedure set forth in Example 1 above. However, two batches (Batch 871112A and Batch 871113A) received a 4% by weight enteric coating and the other two batches (Batch 871116A and Batch 871117B) received a 6% by weight enteric coating. The differences in dissolution and taste mask were compared between the erythromycin granules with a 4% by weight enteric coating (Batches 871112A and 871113A) and the erythromycin granules with a 6% by weight enteric coating (Batches 871116A and 871117B). The results of the comparison are set forth in Table 5 below.

20

25

-33-

Table 5

	Batch	%Ct. Wt.	Time (min)	% Dissolved	Comments
5	871112A	4	90 120	75.8 89.9	Bitter to slight Bitter taste
	871113A	4	90 120	78.7 93.0	Very slight bitter taste
10	871116A	6	90 120	79.5 95.0	No taste
	871117B	6	90 120	79.0 94.0	No taste

15 Dissolution analysis for enteric coated pellets was performed as follows:

90 minutes = 60 minutes in SGF and 30 minutes in SIF.

120 minutes = 60 minutes in SGF and 60 minutes in SIF.

20 * Dissolution analysis based on measured potency.

25 The 6% by weight enteric coated erythromycin (Batches 871116A and 871117B) displayed better dissolution characteristics and better taste mask characteristics than the erythromycin granules with a 4% by weight enteric coating (Batches 871112A and 871113A).

Example 6

Granule Dissolution and Taste Mask
Properties with Three Protective Coats
and Methylene Chloride Enteric Coating
30 Formulation

Microencapsulated granules were prepared in accordance with Example 1 above. However, the enteric coating composition used to coat the seeds comprised 5%

-34-

by weight hydroxypropyl methylcellulose phthalate in a solvent mixture of 75% by weight methylene chloride and 25% by weight methanol.

5

Dissolution and taste mask were tested for these granules in the same manner as in Example 5. The results of these tests are set forth below in Table 6.

-35-

Table 6

<u>Batch</u>	<u>% Ct./Wt.</u>	<u>Time (min.)</u>	<u>% Dissolved</u>	<u>Comment</u>
871030C	6	90 120	85.7* 100.3*	Slight bitter to no taste

* Dissolution data based on theoretical potency.

SUBSTITUTE SHEET

-36-

The dissolution characteristics and taste mask characteristics exhibited by the granules of this example were comparable to those exhibited by the granules of Example 5 (enteric coating composition with an acetone based solvent).

Example 7

Pharmacokinetic Comparison of Erythromycin Dihydrate Microencapsulated Granules and a Conventional Erythromycin Product

A twelve-hour bioavailability study was performed comparing erythromycin microencapsulated granules prepared in accordance with Example 1 above to an equivalent dose of a conventional erythromycin formulation, ERYC[®] (registered trademark of Parke-Davis, Division of Warner-Lambert Company). The study was performed in the following manner.

Twenty-eight subjects were administered a single dose (250 mg) of each formulation (erythromycin microencapsulated granules and ERYC[®]) in a randomized, cross-over food-fasted format with each dose separated by a 7-day washout period.

The subjects were healthy male and female volunteers, 21 to 39 years of age, and weighed within 10% of ideal body weight. Subjects were determined healthy by normal vital organ functions as reflected by medical history, physical examination, and laboratory tests. Females had negative serum pregnancy tests and were either surgically sterilized or using a reliable method of contraception.

The subjects were administered the erythromycin formulation with one teaspoonful of applesauce and 180 ml of water. Subjects with the standardized breakfast were administered the erythromycin formulation after finishing one Egg McMuffin[®] then followed by one hot apple pie and the rest of the beverages (orange juice and coffee).

-37-

Five (5) ml of blood were collected prior to erythromycin administration, and then at 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours after administration. The blood was allowed to clot. Serum was separated by centrifugation within 60 minutes after collection. A seraclear filter was used to clarify the serum. Serum was placed in labelled polypropylene tubes and stored frozen at -20°C.

Erythromycin concentrations were determined by microbiologic assay using Micrococcus lutea. An agar well procedure was performed in 10 mm sterile plastic petri plates containing Antibiotic Media #1 (Difco®), adjusted to pH 8.5 before sterilization.

Mean pharmacokinetic parameters were determined from the samples of the subjects and are reported below in Table 7A.

A repeated measures analysis of variance was used to compare the four treatment regimens. Tukey's method post-hoc multiple comparisons was used to compare mean values between two treatment regimens. P values are reported below in Table 7B (NS = Not Significant, $p > 0.05$).

Table 7A

Mean Pharmacokinetic Parameters

	<u>Regimen A</u>	<u>Regimen B</u>	<u>Regimen C</u>	<u>Regimen D</u>
C _{max}	1.23±0.58	1.16±0.70	0.73±0.55	0.50±0.24
T _{max}	3.06±1.04	3.18±0.89	5.82±1.16	5.29±1.00
T _{lag}	2.02±1.20	2.27±0.80	4.32±1.94	4.33±1.17
Ke	0.424±0.098	0.464±0.168	0.45±0.207	0.446±0.129
Half-Life	1.72±0.40	1.69±0.61	1.64±0.61	1.73±0.66
AUC ₀₋₁₂	3.56±1.92	3.01±1.95	1.77±1.40	1.46±1.40
AUC _{0-∞}	4.16±1.98	3.69±1.95	2.55±1.24	1.56±0.76

Note:

Regimen A = granules without breakfast
 Regimen B = ERYC without breakfast
 Regimen C = granules with breakfast
 Regimen D = ERYC with breakfast

-39-

Table 7B

	C_{max}	T_{max}	T_{lag}	AUC_{0-12}
A to B	NS	NS	NS	NS
A to C	<0.05	<0.05	<0.05	<0.05
B to D	<0.05	<0.05	<0.05	<0.05
C to D	NS	NS	NS	NS

-40-

Of the twenty-eight subjects enrolled, 26 completed the required four treatment regimens. Statistical significance was defined as a p value of 0.05. Statistical analysis of AUC_{0-12} , C_{max} , T_{max} , and T_{lag} demonstrated no differences in relative oral bioavailability between the microencapsulated granule formulation of the present invention and ERYC[®] capsule under either fasting or nonfasting conditions. The mean AUC_{0-12} of Regimen A was 3.56 mg/hr/L compared to 3.01 mg/hr/L for Regimen B. The mean C_{max} , T_{max} , and T_{lag} of Regimen A were similar to Regimen B. The mean AUC_{0-12} of Regimen C was 1.77 mg/hr/L compared to 1.46 mg/hr/L for Regimen D. The mean C_{max} , T_{max} , and T_{lag} were also similar. Administration of the microencapsulated granule formulation of the present invention or ERYC[®] capsule with breakfast had a significant effect on relative oral bioavailability of both products. A decrease in AUC_{0-12} of approximately 50% was seen with the granule formulation and ERYC[®] capsule. A statistically significant decrease in C_{max} was also observed. The time to onset of absorption (T_{lag}) and peak concentration (T_{max}) were significantly prolonged with food.

Visual inspection of the serum erythromycin concentration v time curves demonstrated similar variability in the absorption of both products. In 36 of 104 concentration vs. time profiles, elimination rate constants could not be calculated, as there were inadequate data points clearly in the elimination phase. For this reason, statistical analysis of K_e , half-life, and AUC_{0-12} was not performed. Food also significantly decreased C_{max} and prolonged T_{lag} and T_{max} for both products.

-41-

Example 8

Preparation of Microencapsulated
Erythromycin Granules with
Hydroxypropyl Methylcellulose E-5
as a Binder

Microencapsulated granules were prepared (870102A) in accordance with Example 1 above. However, the active coating composition was composed of 4.5% (w/w) HPMC E-5 30.5% (w/w) Erythromycin and 65% (w/w) Methyl Alcohol. The starting seeds used were 40/60 mesh non-pareils. An 8-fold buildup of the starting seeds was used to produce the final product. The final theoretical potency was about 700 µg/mg (70%).

Although no attempt was made to use smaller starting seeds (60/80) or to perform a 24-fold buildup, this example indicates that HPMC E-5 is almost as good a binder as the polyethylene oxide/polyethylene glycol mixture. The results of these experiments are shown in Table 8. This binder produced yields of better than 90% in the desired size range at each of the processing steps (Active I, Active II and Active III).

Example 9

Preparation of Microgranules of
Erythromycin with Hydroxypropyl
Methylcellulose E-15 as a Binder

Microencapsulated granules were prepared (870120B) in accordance with Example 1 above. However, the active coating composition was composed of 2.1% (w/w) HPMC E-15, 32.7% (w/w) Erythromycin, 0.42% (w/w) PEG 400 and 64.8% (w/w) Methyl Alcohol. The starting seeds were 40/60 mesh non-pareils. An 8-fold buildup of the starting seeds was intended to produce the final

-42-

product. The results of these experiments are shown in Table 8. This binder system did not produce active seeds resilient enough to withstand the extended processing time associated with the required high potency level. It is possible that alteration of processing conditions or the solvent system could improve the results so that a product of this nature might be deemed acceptable.

Example 10

Preparation of Microgranules of Erythromycin with Hydroxypropyl Methylcellulose Phthalate HP 55S as a Binder

Microencapsulated granules were prepared (870305B & 870312B) in accordance with Example 1 above. However, the active coating composition was composed of 2.8% (w/w) HPMCP HP 55S, 32.3% (w/w) Erythromycin, 52.3% (w/w) Methyl Alcohol, and 11.7% w/w Ethyl Acetate. The starting seeds used were 40/60 mesh non-pareils. An 8-fold buildup of the starting seeds was intended to produce the final product. The final theoretical potency was 699 μ g/mg. The results of these experiments are shown in Table 8.

This binder produced yields of better than 90% in the desired size range at each of the processing steps. However, a high level of residual Ethyl Acetate was found (3.4% w/w). Although no attempt was made to use smaller starting seeds (60/80) or to perform a 24-fold buildup, this example indicates that HPMCP HP 55S is almost as good a binder as the polyethylene oxide/polyethylene glycol mixture. When Ethyl Acetate was removed from the solvent system, the binder did not produce active seeds resilient enough to withstand the extended processing times necessary for the high potency

-43-

level. It is possible that further alteration of processing conditions or the solvent system could improve the results so that a product of this nature might be deemed acceptable.

5

Example 11

Preparation of Microgranule of
Erythromycin with Hydroxypropyl
Cellulose as a Binder

10 Microencapsulated granules were prepared (870116C) in
accordance with Example 1 above. However, the active
coating composition was composed of 2.5% (w/w) HPC,
32.5% (w/w) Erythromycin, and 65% (w/w) Methyl Alcohol.
15 The starting seeds used were 40/60 mesh non-pareils. An
8-fold buildup of the starting seeds was intended to
produce the final product. The results of these
experiments are shown in Table 8. This binder did not
produce active seeds resilient enough to withstand the
extended processing time associated with the required
20 high potency level. It is possible that alteration of
processing conditions or the solvent system could
improve the results so that a product of this nature
might be deemed acceptable.

Example 12

25

Preparation of Microgranules of
Erythromycin with a 50/50 Mixture
of HPMC E-15 and HPC

30 Microencapsulated granules (870124B) were prepared in
accordance with Example 1 above. However, the active
coating composition was composed of 0.95% (w/w) HPMC E-
15, 0.95% (w/w) HPC, 39.5% (w/w) Erythromycin, and 58.6%
(w/w) Methyl Alcohol. The starting seeds used were
40/60 mesh non-pareils. An 8-fold buildup of the

-44-

starting seeds was intended to produce the final product. The results of these experiments are shown in Table 8. This binder system did not produce active seeds resilient enough to withstand the extended processing time associated with the required high potency level. It is possible that further alteration of processing conditions or the solvent system could improve the results so that a product of this nature might be deemed acceptable

Example 13

Preparation of Microgranules of Erythromycin with Polyvinyl- pyrrolidone as a Binder

Microencapsulated granules were prepared (861226B) in accordance with Example 1 above. However, the active coating composition was composed of 4.55% (w/w) PVP K-30, 30.4% (w/w) erythromycin, and 65.0% (w/w) water. The starting seeds used were 40/60 mesh non-pareils. An 8-fold buildup of the starting seeds was intended to produce the final product. The results of this experiment are shown in Table 8. This binder did not produce active seeds resilient enough to withstand the extended processing time associated with the required high potency level. It is possible that alteration of processing conditions or the solvent system could improve the results so that a product of this nature might be deemed acceptable.

-45-

Table 8

ACTIVE I

Example	Binder	Lot No.	% Usable (within desired range)	% Recovered (amt. of material discharged)	Solvent System	(Stage of Active)	Comments
8	HPMC E-5	861229A	93.8	93.9	Methanol	1 of 3	
9	HPMC E-15	870115A	91.5	92.0	Methanol	1 of 3	
10	HPMCP						
	HP 55S	870305B	93.6	95.3	Methanol/ Ethyl Acetate (82%/18%)	1 of 2	
11	HPC	870116C	89.4	89.6	Methanol	1 of 3	Did poorly in comparison to other binders tested
12	HMPC E-15/ HPC (50/50)						
		870124B	92.5	93.4	Methanol	1 of 3	
13	PVP 29/32	861226B	79.5	81.1	Methanol	1 of 3	

-46-

Table 8 - cont'd

ACTIVE II

Example	Binder	Lot No.	% Usable (within desired range)	% Recovered (amt. of material discharged)	Solvent System	(Stage of Active)	Comments
8	HPMC E-5	861231A	94.6	94.6	Methanol	2 of 3	
9	HPMC E-15	870120B	83.1	96.4	Methanol	2 of 3	
10	HPMCP						
	HP 55S	870312B	94.9	97.1	Methanol/ Ethyl Acetate (82%/18%)	2 of 2	
11	HPC		----	----	-----	-----	This binder system showed inability to withstand further processing
12	HMPC E-15/ HPC (50/50)		----	----	-----	-----	This binder system showed inability to withstand further processing

-47-

Table 8 - cont'd

ACTIVE III

Example	Binder	Lot No.	% Usable (within desired range)	% Recovered (amt. of material discharged)	Solvent System	(Stage of Active)	Comments
8	HPMC E-5	870102A	91.8	96.0	Methanol	3 of 3	
9	HPMC E-15		----	----	-----	-----	This binder system showed inability to withstand further processing
10	HPMCP HP 55S		----	----	-----	-----	This binder was used in an active process that required only two sets
11	HPC		----	----	-----	-----	This binder system showed inability to withstand further processing
12	HMPD E-15/ HPC (50/50)		----	----	-----	-----	This binder system showed inability to withstand further processing

NOTE: The objective of a finished active product is an 8 to 1 weight gain. This was accomplished in a three step process with the exception of (HPMC-P H 55S) which required only two steps.

Therefore, Active II (HPMC-P HP 55S) is equivalent to (HPMC E-5) Active III.

Example 14

Effect of Polyethylene Oxide
Binder Level in the Absence
of Protective Coating Layers

5 Erythromycin microencapsulated granules were prepared
in accordance with Example 1. However, in some of the
batches, polyethylene oxide alone was used as the binder
instead of the polyethylene oxide/polyethylene glycol
mixture. Additionally, the processing of the
10 microgranules was stopped at different stages and the
granules were tested to determine their dissolution
characteristics in simulated gastric fluid (SGF) and/or
simulated intestinal fluid (SIF). Table 9, below shows
the results of these tests.

- 49 -

Table 9

Batch	Stage	Time	% Dissolution	% Ct Wt	Yield (%)	Comments
871005C	Enteric	90 min.	34.7	8	69	Act.: 8% binder (Polyox)
871007A	Enteric	90 min.	34.5	15	97	Act.: 8% binder (Polyox)
871005A	Active	30 min.	69.4 *	N/A	96	8% binder (Polyox)
871008D	Active	30 min.	106.6	N/A	69	5% binder (Polyox)
871013B	Active	30 min.	94.0	N/A	92	8% binder (Polyox/PEG)
871017A	Active	30 min.	86.6 *	N/A	95	8% (Polyox/PEG), 1 pr. ct

Dissolution analysis for the active pellets was performed in SIF only.

Dissolution analysis for enteric coated pellets was performed as follows:

90 minutes = 60 minutes in SGF and 30 minutes in SIF

* Dissolution data based on theoretical potency. All other results based

-50-

The results shown above in Table 9 suggest a reaction between polyethylene oxide and erythromycin. The percentage of dissolution was unacceptably low in all the batches in which an 8% by weight polyethylene oxide binder was used (Batches 871005C, 871007A, 871005A). However, the lowering of the polyethylene oxide binder to 5% by weight resulted in a dissolution improvement, but the seeds were not resilient enough to withstand the extended processing time associated with the required high potency level as indicated by low values for yield (Batch 871008D).

Additionally, the mixture of polyethylene oxide and polyethylene glycol as a binder at 8% by weight resulted in microgranules with acceptable dissolution characteristics (Batch 871013A) but slightly reduced yield. The use of a polyethylene oxide/polyethylene glycol protective coating did slow the dissolution somewhat (see Batch 871017A) but raised yield slightly.

Example 15

Comparison of Inventive Microgranules to ERYC[®] Granules

Table 10, below, compares the present inventive erythromycin microgranules to ERYC[®] erythromycin granules. The critical characteristics compared are size, potency, sphericity, bulk density and activity density.

-51-

Table 10

Inventive Microgranules to
ERYC® Granules

Product Name	Mesh Size Microns	Screen Analysis					
		Weight Percent Larger Than Stated Size					
		14	16	18	20	25	30 35
		1410	1190	1000	240	710	590 500
<hr/>							
ERYC® (Erythromycin)		66.5	29.2	3.1	0.5	0.2	0.1
Present Invention (Erythromycin) (Batch 870309A)		5.0	49.0	36.0	8.0	2.0	

SUBSTITUTE SHEET

-52-

Table 10 - cont'dInventive Microgranules to
ERYC® Granules

Product Name	Potency Weight %	Sphericity*	Percent	Bulk Density	Activity Density
ERYC® (Erythromycin)	57.3	81.7		0.741	0.425
Present Invention (Erythromycin) (Batch 870309A)	67.4	90.5		0.668	0.450

* Sphericity was determined by a "cut and weigh" method. Photomicrographs were taken of individual particles. A template was then used to draw a circle circumscribing each particle. These circles were then cut out and weighed. Subsequently, the outline of the particle itself was cut out of the original circle and the remainder weighed. The weight of the remainder divided by the weight of the original circle and multiplied by 100 gave Sphericity Percent.

-53-

Table 10 indicates that presently available erythromycin granules do not meet all the required specifications of the present invention.

5 While the invention has been disclosed by reference to the details of various embodiments of the invention, it is understood that this disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will occur to those skilled in the art, within the spirit of the invention
10 and the scope of the appended claims.

-54-

WHAT IS CLAIMED IS:

1. A microencapsulated granule comprising a mixture of erythromycin and a binder as an active coating in a ratio of about 5:1 to about 15:1 on a seed, said granule having an activity density greater than about 0.300 g/ml and a diameter less than about 1000 microns.
2. The microencapsulated granule of claim 1 wherein the binder may be selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, polyethylene glycol, polyethylene oxide, hydroxypropyl cellulose, cellulose acetate phthalate, polyvinyl acetate phthalate and combinations thereof.
3. The microencapsulated granule of claims 1 or 2, or wherein the mixture is applied to the seed as an active coating composition comprising about 15% by weight to about 40% by weight erythromycin, about 1% by weight to about 4% by weight binder and a solvent.
4. The microencapsulated granule of claim 3 wherein the solvent may be selected from the group consisting of water, ethanol, methanol, isopropanol, acetone, methylene chloride, chloroform, ethyl acetate, carbon tetrachloride, benzene, methyl ethyl ketone and combinations thereof.
5. The microencapsulated granule of any of the preceding claims further comprising a mixture of about 52% by weight to about 72% by weight polyethylene oxide and about 28% by weight to about 48% by weight polyethylene glycol applied as a protective coating over the active coating.

-55-

6. The microencapsulated granule of claim 5 wherein the protective coating is applied as a protective coating composition comprising about 10% by weight of the mixture of polyethylene oxide and polyethylene glycol and a solvent.
7. The microencapsulated granule of claim 6 wherein the solvent is water.
8. The microencapsulated granule of claims 5, 6 or 7 further comprising an enteric coating over the protective coating, said enteric coating selected from the group consisting of cellulose acetate phthalate, polyvinyl acetate phthalate, acrylic resins, shellac, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate and combinations thereof.
9. The microencapsulated granule of claim 8 wherein the enteric coating comprises about 3% by weight to about 10% by weight hydroxypropyl methylcellulose phthalate.
10. The microencapsulated granule of claim 9 wherein the enteric coating is applied as an enteric coating composition comprising about 5% by weight to about 10% by weight hydroxypropyl methylcellulose phthalate and a solvent.
11. The microencapsulated granule of claim 10 wherein the solvent may be selected from the group consisting of acetone, a mixture of acetone and methanol and a mixture of methylene chloride and methanol.

-56-

12. The microencapsulated granule of claims 9, 10 or 11 further comprising more than one active coating and more than one protective coating.
13. The microencapsulated granule of claim 12 wherein the active coatings and protective coatings are applied alternatively and in equal numbers.
14. The microencapsulated granule of claim 13 wherein three active coatings are applied and three protective coatings are applied.
15. The microencapsulated granule of claims 12, 13 or 14 further comprising a sufficient amount of antistatic agent to coat the granule, said antistatic agent selected from the group consisting of silicon dioxide, talc, magnesium stearate, calcium stearate, polacrillin, stearic acid or combinations thereof.
16. The microencapsulated granule of claim 15 wherein the antistatic agent comprises about 0.75% by weight silicon dioxide.
17. A dosage delivery system comprising a plurality of erythromycin microencapsulated granules as described in any of the preceding claims compressed into a tablet.
18. A dosage delivery system comprising a plurality of erythromycin microencapsulated granules as described in any of the preceding claims contained in a water soluble capsule.

19. A dosage delivery system comprising a plurality of erythromycin microencapsulated granules as described in any of the preceding claims contained in a flowable material dispenser.
20. A dosage delivery system comprising a plurality of erythromycin microencapsulated granules as described in any of the preceding claims, contained in unit dose packets, sachets or blisters.
21. A process for manufacturing erythromycin microencapsulated granules comprising:
 - (a) applying an active coating composition to an inert seed to form an active seed; and
 - (b) applying a protective coating composition to the active seed;said active coating composition comprising about 15% by weight to about 40% by weight erythromycin, about 1% by weight to about 4% by weight binder and a solvent; and
said protective coating composition comprising about 10% by weight of a mixture of polyethylene oxide and polyethylene glycol and a solvent.
22. A process for manufacturing erythromycin microencapsulated granules comprising:
 - (a) applying an active coating composition to an active drug crystal to form an active seed; and
 - (b) applying a protective coating composition to the active seed;said active coating composition comprising about 15% by weight to about 40% by weight erythromycin, about 1% by weight to about 4% by weight binder and a solvent; and

-58-

said protective coating composition comprising about 10% by weight of a mixture of polyethylene oxide and polyethylene glycol and a solvent.

23. The process of claims 21 or 22 wherein:
- the binder may be selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide, hydroxypropyl cellulose, cellulose acetate phthalate, polyvinyl acetate phthalate and combinations thereof;
 - the solvent for the active coating composition and may be selected from the group consisting of water, ethanol, methanol, isopropanol, acetone, methylene chloride, chloroform, ethyl acetate, carbon tetrachloride, benzene, methyl ethyl ketone and combinations thereof;
 - the solvent for the protective coating composition is water; and
 - the protective coating composition mixture of polyethylene oxide and polyethylene glycol comprises about 52% by weight to about 72% by weight polyethylene oxide and about 28% by weight to about 48% by weight polyethylene glycol.
24. The process of claim 23 further comprising more than one active coating composition application and more than one protective coating composition application.
25. The process of claim 24 wherein the active coating composition and protective coating composition are applied alternatively and in equal numbers.

-59-

26. The process of claim 25 wherein the active coating composition and the protective coating composition are each applied three times.
27. The process of claim 26 further comprising applying an enteric coating composition after the last application of protective coating composition.
28. The process of claim 27 wherein the enteric coating composition comprises about 5% by weight to about 10% by weight hydroxypropyl methylcellulose phthalate and a solvent.
29. The process of claim 28 wherein the solvent may be selected from the group consisting of acetone, a mixture of acetone and methanol and a mixture of methylene chloride and methanol.
30. The process of claims 27, 28 or 29 further comprising applying a sufficient amount of an antistatic agent to coat the microgranules.
31. The process of claim 30 wherein the antistatic agent may be selected from the group consisting of silicon dioxide, talc, magnesium stearate, calcium stearate, polacrillin, stearic acid and combinations thereof.
32. The process of claims 30 or 31 wherein the active coating composition, the protective coating composition, the enteric coating composition and the antistatic agent are applied by use of a fluidized bed technique.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 89/03105

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 9/54, A 61 K 31/71		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	A 61 K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	NL, A, 7614310 (BEECHAM GROUP) 5 July 1977, see page 8, lines 19-35; claims --	1-32
Y	US, A, 4758437 (T. SONOBE) 19 July 1988, see column 1, line 59 - column 2, line 20; example 1; claims --	1-32
Y	EP, A, 0012495 (BEECHAM) 25 June 1980, see page 2, lines 3-14; claims --	1-32
Y	WO, A, 83/00284 (KEY PHARMACEUTICALS) 3 February 1983, see abstract; page 1, paragraph 3; claims & US, A, 4387118 cited in the application --	1-32
X	FR, A, 2331375 (AB HASSLE) 10 June 1977, see examples 3,4; claims; page 4, last paragraph ----	1-32
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
29th October 1989	15. 11. 89	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	T.K. WILTIS	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8903105

SA 30147

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 08/11/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NL-A- 7614310	05-07-77	GB-A- 1561301	20-02-80
		AU-B- 513446	04-12-80
		AU-A- 2103777	13-07-78
		BE-A- 849632	20-06-77
		CA-A- 1089364	11-11-80
		DE-A- 2658309	14-07-77
		FR-A,B 2336919	29-07-77
		JP-A- 52083916	13-07-77
		SE-B- 432524	09-04-84
		SE-A- 7614576	03-07-77
		US-A- 4177254	04-12-79

US-A- 4758437	19-07-88	None	

EP-A- 0012495	25-06-80	US-A- 4423033	27-12-83

WO-A- 8300284	03-02-83	CA-A- 1202899	08-04-86
		DE-A- 3278491	23-06-88
		EP-A,B 0083372	13-07-83
		US-A- 4587118	06-05-86

FR-A- 2331375	10-06-77	SE-B- 418247	18-05-81
		AT-B- 354636	25-01-79
		AU-B- 508266	13-03-80
		AU-A- 1961776	25-05-78
		BE-A- 848406	17-05-77
		CA-A- 1075031	08-04-80
		DE-A,C 2651176	18-05-77
		GB-A- 1560841	13-02-80
		JP-A- 52083921	13-07-77
		LU-A- 76215	06-06-77
		NL-A- 7612728	20-05-77
		SE-A- 7512883	18-05-77
		US-A- 4289795	15-09-81
		US-A- 4341759	27-07-82

EPO FORM P4179

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82